Nontransplant options for portomesenteric thrombosis.

Authors :: Hibi T
Source :: Current opinion in organ transplantation [Curr Opin Organ Transplant] 2022 Apr 01; Vol. 27 (2), pp. 144-147.
Publication Year :: 2022
Abstract: Purpose of Review: Portomesenteric thrombosis (PMT) is a serious condition encountered mainly in cirrhotic patients awaiting liver transplantation. More recently, this potentially fatal complication has been described after bariatric surgery and inflammatory bowel disease. Several consensus guidelines have been published over the past few years and this mini review was conducted to discuss updated nontransplant treatment options based on currently available evidence.<br />Recent Findings: Anticoagulation is the mainstay of treatment for PMT involving <50% of the main portal vein. Transjugular intrahepatic portosystemic shunt are usually preserved for patients with more extensive disease or those with clinically significant portal hypertension that are treatment refractory.<br />Summary: The extent of PMT, response to therapy, and complications related with PMT are the determinants of therapy.<br /> (Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.)